Usefulness of data from magnetic resonance imaging to improve prediction of dementia: Population based cohort study

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Stephan, Blossom C M ^a   Tzourio, Christophe ^b,c   Auriacombe, Sophie ^d   Amieva, Hélène ^b   Dufouil, Carole ^b,c   Alpérovitch, Annick ^b   Kurth, Tobias ^b,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d University Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

AGE; AGED; ALCOHOL CONSUMPTION; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CARDIOVASCULAR DISEASE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DECISION MAKING; DEMENTIA; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; EDUCATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENETIC RISK; GENOTYPE; HEALTH; HEALTH STATISTICS; HEALTH STATUS; HIPPOCAMPAL VOLUME; HUMAN; LAWTON AND BRODY SCALE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; WHITE MATTER LESION; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; FRANCE; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREVALENCE; PROSPECTIVE STUDY; REPRODUCIBILITY;

AGED; COMORBIDITY; DEMENTIA; DISEASE PROGRESSION; FOLLOW-UP STUDIES; FRANCE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84939223770     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2863     Document Type: Article

References (58)

1. Alzheimer's Disease International. World Alzheimer Report. 2009. www.alz.co.uk/research/files/WorldAlzheimerReport.pdf.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42.
3. Barnes DE, Covinsky KE, Whitmer RA, et al. Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009." Dementia risk indices: a framework for identifying individuals with a high dementia risk. Alzheimers Dement 2010; 6: 138-41.
4. Barnes DE, Covinsky KE, Whitmer RA, et al. Predicting risk of dementia in older adults: the late-life dementia risk index. Neurology 2009; 73: 173-9.
5. Reitz C, Tang M-X, Schupf N, et al. A summary risk score for the prediction of alzheimer disease in elderly persons. Arch Neurol 2010; 67: 835-41.
6. Exalto LG, Biessels GJ, Karter AJ, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol 2013; 1: 183-90.
7. Stephan BCM, Kurth T, Matthews FE, et al. Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol 2010; 6: 318-26.
8. Nakata E, Kasai M, Kasuya M, et al. Combined memory and executive function tests can screen mild cognitive impairment and converters to dementia in a community: the Osaki-Tajiri project. Neuroepidemiology 2009; 33: 103-10.
9. Nielsen H, Lolk A, Andersen K, et al. Characteristics of elderly who develop Alzheimer's disease during the next two years-a neuropsychological study using CAMCOG. The Odense Study. Int J Geriatr Psychiatry 1999; 14: 957-63.
10. Tierney MC, Yao C, Kiss A, et al. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005; 64: 1853-9.
11. Hogan DB, Ebly EM. Predicting who will develop dementia in a cohort of Canadian seniors. Can J Neurol Sci 2000; 27: 18-24.
12. Barnes DE, Beiser AS, Lee A, et al. Development and validation of a brief dementia screening indicator for primary care. Alzheimers Dement 2014; 10: 656-65.e1.
13. Chary E, Amieva H, Peres K, et al. Short-versus long-term prediction of dementia among subjects with low and high educational levels. Alzheimers Dement 2013; 9: 562-71.
14. Madureira S, Verdelho A, Moleiro C, et al. Neuropsychological predictors of dementia in a three-year follow-up period: data from the LADIS study. Dement Geriatr Cogn Disord 2010; 29: 325-34.
15. Ohara T, Ninomiya T, Kubo M, et al. Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the Hisayama study. J Am Geriatr Soc 2011; 59: 1074-9.
16. Okereke OI, Pantoja-Galicia N, Copeland M, et al. The SIST-M: predictive validity of a brief structured clinical dementia rating interview. Alzheimer Dis Assoc Disord 2012; 26: 225-31.
17. Reitz C, Tang MX, Schupf N, et al. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol 2010; 67: 835-41.
18. Restaino M, Matthews FE, Minett T, et al. Predicting risk of 2-year incident dementia using the CAMCOG total and subscale scores. Age Ageing 2013; 42: 649-53.
19. Tierney MC, Moineddin R, McDowell I. Prediction of all-cause dementia using neuropsychological tests within 10 and 5 years of diagnosis in a community-based sample. J Alzheimers Dis 2010; 22: 1231-40.
20. Song X, Mitnitski A, Rockwood K. Nontraditional risk factors combine to predict Alzheimer disease and dementia. Neurology 2011; 77: 227-34.
21. Song X, Mitnitski A, Rockwood K. Age-related deficit accumulation and the risk of late-life dementia. Alzheimers Res Ther 2014; 6: 54.
22. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
23. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
24. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
25. 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 2003; 22: 316-25.
26. Institut national de la statistique et des études économiques. Paris, 2002. www.insee.fr.
27. Maillard P, Delcroix N, Crivello F, et al. An automated procedure for the assessment of white matter hyperintensities by multispectral (T1, T2, PD) MRI and an evaluation of its between-centre reproducibility based on two large community databases. Neuroradiology 2008; 50: 31-42.
28. Godin O, Dufouil C, Maillard P, et al. White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. Biol Psychiatry 2008; 63: 663-9.
29. Maillard P, Crivello F, Dufouil C, et al. Longitudinal follow-up of individual white matter hyperintensities in a large cohort of elderly. Neuroradiology 2009; 51: 209-20.
30. Dufouil C, Godin O, Chalmers J, et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009; 40: 2219-21.
31. Godin O, Tzourio C, Rouaud O, et al. Joint effect of white matter lesions and hippocampal volumes on severity of cognitive decline: the 3C-Dijon MRI study. J Alzheimers Dis 2010; 20: 453-63.
32. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341: c3666.
33. Jack CR, Jr., Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600.
34. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
35. Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973; 123: 467-70.
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. AMA, 1994.
37. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
38. Lawton MP Scales to measure competence in everyday activities. Psychopharmacol Bull 1988; 24: 609-14.
39. Benton AL Manuel pour l'Application Clinique du Test de Retention Visuelle. Applications cliniques et expérimentales. Centre de Psychologie Appliquée, 1965.
40. Wechsler D. Wechsler memory scale. Psychological Corporation, 1975.
41. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 1990; 77: 147-60.
42. Newson RB Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J 2010; 10: 339-58.
43. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72; 207-12.
44. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004; 23: 723-48.
45. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-74.
46. Rubin DB Multiple imputation for nonresponse in surveys. Wiley, 1987.
47. Zahuranec DB, Sánchez BN, Brown DL, et al. Computed tomography findings for intracerebral hemorrhage have little incremental impact on post-stroke mortality prediction model performance. Cerebrovasc Dis 2012; 34: 86-92.
48. Kerr KF, McClelland RL, Brown ER, et al. Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol 2011; 174: 364-74.
49. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med 2014; 33: 3405-14.
50. Richard E, Schmand BA, Eikelenboom P, et al. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ Open 2013; 3: e002541.
51. Matthews FE, Stephan BC, McKeith IG, et al. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 2008; 56: 1424-33.
52. Harrison SL, Sajjad A, Bramer WM, et al. Exploring strategies to operationalize cognitive reserve: a systematic review of reviews. J Clin Exp Neuropsychol 2015; 37: 253-64.
53. Perneczky R, Pohl C, Sorg C, et al. Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriatr Psychiatry 2006; 21: 158-62.
54. Peres K, Chrysostome V, Fabrigoule C, et al. Restriction in complex activities of daily living in MCI: impact on outcome. Neurology 2006; 67: 461-6.
55. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
56. Den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133: 1163-72.
57. Begg CB, Gonen M, Seshan VE. Testing the incremental predictive accuracy of new markers. Clin Trials 2013; 10: 690-2.
58. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med 2014; 33: 3405-14.